Silo Pharma financials
$1.61−2.42%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 |
|---|---|---|---|---|
| Revenue | $72.1K | $72.1K | $72.1K | $72.1K |
| Gross profit | $27.8K | $66.3K | $66.3K | $66.3K |
| Gross margin | 38.6% | 91.9% | 91.9% | 91.9% |
| Operating income | -$4.3M | -$4.7M | -$3.9M | -$3.6M |
| Net income | -$4.2M | -$4.4M | -$3.7M | -$3.9M |
| Net margin | −5863.5% | −6092.6% | −5132.6% | −5420.9% |
| Diluted EPS | $-0.50 | $-1.19 | $-1.20 | $-1.71 |
| EBITDA | -$4.3M | -$4.7M | -$3.8M | -$3.6M |
| Operating cash flow | -$4.7M | -$3.8M | -$3.2M | -$3.5M |
| Free cash flow | -$4.7M | -$3.8M | -$3.2M | -$3.5M |
| Diluted shares | 8.4M | 3.7M | 3.1M | 2.3M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|
| Cash & equivalents | $4.7M | $3.9M | $3.5M | $11.4M |
| Short-term investments | $2.1M | $3.2M | $4.1M | $3.1K |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $7.6M | $7.4M | $7.7M | $11.6M |
| Total liabilities | $1.3M | $2.4M | $1.6M | $1.3M |
| Shareholders' equity | $6.3M | $5.0M | $6.2M | $10.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology